Immunotherapy – Page 3

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

9 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.

Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies

10 months ago talkbio0Tagged Biotechnology, Immunotherapy, Inflammation, multi-specific antibodies, Neoplasms, Numab, Series C

Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology

Citius Oncology Explores Strategic Alternatives Ahead of LYMPHIR Commercial Launch

10 months ago talkbio0Tagged Citius Oncology, commercial, Immunotherapy, launch, LYMPHIR, strategic alternatives

Citius Oncology, LYMPHIR, strategic alternatives, commercial launch, cutaneous T-cell lymphoma, immunotherapy

FDA Approves Subcutaneous Formulation of Bristol Myers’ Opdivo for Solid Tumor Indications

10 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, hyaluronidase, Immunotherapy, Myers, nivolumab, squibb, Subcutaneous Opdivo, United States Food and Drug Administration

FDA approval, subcutaneous Opdivo, Bristol Myers Squibb, cancer treatment, immunotherapy, nivolumab, hyaluronidase

FDA Approves UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma, Marking a New Era in Skin Cancer Treatment

11 months ago talkbio0Tagged Approved, checkpoint inhibitor, cosibelimab-ipdl, Immunotherapy, Malignant neoplasm of skin, Squamous cell carcinoma, Squamous cell carcinoma of skin, United States Food and Drug Administration, UNLOXCYT

UNLOXCYT, cosibelimab-ipdl, FDA approval, advanced cutaneous squamous cell carcinoma (cSCC), checkpoint inhibitor, immunotherapy, skin cancer treatment.

Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Genmab, GlyMab platform, Immunotherapy, licensing agreement, Monoclonal Antibodies, Scancell Holdings

Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies

Carolyn Bertozzi’s Valora Therapeutics Launches with $30M Seed Round to Develop Sugar-Based Immunotherapies

11 months ago talkbio0Tagged Bertozzi, Carolyn, Immunotherapy, seed round, sugar-based treatments, Valora

Carolyn Bertozzi, Valora Therapeutics, immunotherapy, sugar-based treatments, biotech startup, $30M seed round

A Decade of Progress: Immuno-oncology on the Cusp of a New Era

12 months ago talkbio0Tagged Antibodies, Bispecific, cancer care, Cancer Research, Cancer Therapeutic Procedure, checkpoint inhibitors, immuno-oncology, Immunotherapy

Immuno-oncology, checkpoint inhibitors, bispecific antibodies, cancer treatment, immunotherapy, cancer research, future of cancer care.

BioNTech Beats Q3 Expectations but Trims Full-Year Revenue Guidance Amid COVID-19 Vaccine Sales

12 months ago talkbio0Tagged BioNTech, COVID19 (disease), earnings, Immunotherapy, mRNA-based, Oncology Development, revenue guidance, Vaccines

BioNTech, Q3 earnings, COVID-19 vaccine, Revenue guidance, Oncology development, mRNA-based immunotherapies

AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology

12 months ago talkbio0Tagged AbbVie, Biological Factors, EvolveImmune, Immunotherapy, Next-Generation Cancer, Oncology Collaboration, T-Cell Engager Technology, Tumor cells, malignant

AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies